Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,388 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,388 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01077869 | A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of… | — | terminated | Mar 1, 2010 | University Hospital, Ghent | poor recruitment rate | Enrollment / accrual |
| NCT00326911 | Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic… | Phase 2 | terminated | May 17, 2006 | Eli Lilly and Company | The planned enrollment was 130 patients and the study was halted prematurely due to lack of… | Efficacy / futility |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Phase 2 | terminated | Jun 12, 2003 | Teva Branded Pharmaceutical Products R&D, Inc. | not stated | Not stated |
| NCT00117312 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of… | Phase 2 | terminated | Jul 6, 2005 | Ferring Pharmaceuticals | After 190 weeks \[7 patients left\] it was terminated for administrative reasons | Other (stated, no rule matched) |
| NCT00215657 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of… | Phase 2 | terminated | Sep 22, 2005 | Ferring Pharmaceuticals | The doses were not effective in maintaining testosterone suppression | Other (stated, no rule matched) |
| NCT00234468 | Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | Phase 3 | terminated | Oct 7, 2005 | AstraZeneca | Closed due to insufficient recruitment | Enrollment / accrual |
| NCT00245466 | Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix… | Phase 2 | terminated | Oct 28, 2005 | Ferring Pharmaceuticals | The maintenance doses were too low to maintain testosterone suppression | Other (stated, no rule matched) |
| NCT00494611 | A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients | Phase 1 | terminated | Jul 2, 2007 | St. Luke's-Roosevelt Hospital Center | Unable to recruit subjects in timely fashion for the study | Enrollment / accrual |
| NCT00232206 | Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer | Phase 2 | terminated | Oct 4, 2005 | Providence Health & Services | study terminated due to slow accrual | Enrollment / accrual |
| NCT00306267 | A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000… | Phase 2 | terminated | Mar 23, 2006 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Study stopped as it would not address important survival concerns raised in other recently… | Other (stated, no rule matched) |
| NCT00790894 | Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)(HIT) | Phase 2 | terminated | Nov 14, 2008 | Hellenic Cooperative Oncology Group | The low accrual rate of the study (25% of the expected accrual rate) | Enrollment / accrual |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent… | Phase 2 | terminated | Feb 13, 2006 | Novartis | Lack of efficacy | Efficacy / futility |
| NCT01194193 | Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours | Phase 1 | withdrawn | Sep 2, 2010 | AstraZeneca | Amendment to study compound development programme | Other (stated, no rule matched) |
| NCT00470340 | Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients(GEMOXIAL) | Phase 3 | terminated | May 7, 2007 | Assistance Publique - Hôpitaux de Paris | during the study | Other (stated, no rule matched) |
| NCT00193024 | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer | Phase 2 | terminated | Sep 19, 2005 | SCRI Development Innovations, LLC | not stated | Not stated |
| NCT00193102 | Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer | Phase 2 | terminated | Sep 19, 2005 | SCRI Development Innovations, LLC | not stated | Not stated |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone… | Phase 2 | withdrawn | Dec 20, 2007 | University of Arkansas | Poor accrual | Enrollment / accrual |
| NCT00216073 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | Lack of patient accrual | Enrollment / accrual |
| NCT00216138 | Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | Interim analysis results did not meet criteria for second stage of trial | Efficacy / futility |
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | Study terminated due to low patient enrollment. | Enrollment / accrual |
| NCT00216164 | Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | Study terminated due to lack of response at the first efficacy analysis | Efficacy / futility |
| NCT00216216 | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | The results from the interim analysis were not favorable to continue this trial. | Efficacy / futility |
| NCT00522457 | Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast… | Phase 2 | terminated | Aug 29, 2007 | Neovii Biotech | change in development plan, not due to safety concerns. | Safety / toxicity |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Sep 13, 2005 | Hadassah Medical Organization | PI is no longer work at Hadassah | Other (stated, no rule matched) |
| NCT01232881 | Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer | — | terminated | Nov 2, 2010 | Hoosier Cancer Research Network | funding terminated | Funding |
| NCT00083434 | Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or… | Phase 3 | terminated | May 26, 2004 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | This study was stopped because of an inadequate rate of enrollment. | Enrollment / accrual |
| NCT00381693 | Azacitidine in Treating Patients With Myelofibrosis | Phase 2 | terminated | Sep 28, 2006 | Mayo Clinic | Due to lack of accrual and trial has demonstrated too little clinical benefit | Enrollment / accrual |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | Phase 2 | terminated | Sep 18, 2007 | Columbia University | Poor accrual | Enrollment / accrual |
| NCT00226512 | To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to… | Phase 3 | withdrawn | Sep 27, 2005 | Hadassah Medical Organization | the PI is no longer work at Hadassah | Other (stated, no rule matched) |
| NCT00348842 | Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer… | Phase 2 | withdrawn | Jul 6, 2006 | Hadassah Medical Organization | not stated | Not stated |
| NCT01330823 | L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)(CARPAN) | Phase 3 | suspended | Apr 7, 2011 | University Medicine Greifswald | after interims analysis standard errors for inflammatory and nutritional markers varied widely,… | Other (stated, no rule matched) |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | Phase 1 | terminated | Aug 29, 2007 | Exelixis | Due to emerging safety data | Safety / toxicity |
| NCT00187005 | Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Phase 3 | terminated | Sep 16, 2005 | St. Jude Children's Research Hospital | Toxicity | Safety / toxicity |
| NCT01012804 | Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer | — | withdrawn | Nov 13, 2009 | Georgetown University | not stated | Not stated |
| NCT00728533 | Open-Label, Randomised Parallel-Group Study | Phase 3 | withdrawn | Aug 6, 2008 | Ferring Pharmaceuticals | Terminated due to awaiting data from Phase II study. | Other (stated, no rule matched) |
| NCT00049959 | Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple… | Phase 3 | terminated | Nov 19, 2002 | QLT Inc. | not stated | Not stated |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell… | Phase 1 / Phase 2 | withdrawn | Jul 27, 2010 | Charite University, Berlin, Germany | insufficient enrollment | Enrollment / accrual |
| NCT00496067 | Uterine Artery Occlusion for Fibroid Related Bleeding | N/A | terminated | Jul 4, 2007 | Ethicon, Inc. | Data required further pilot work to be undertaken. | Other (stated, no rule matched) |
| NCT00540280 | Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative… | Phase 3 | suspended | Oct 5, 2007 | King Faisal Specialist Hospital & Research Center | Follow up only | Other (stated, no rule matched) |
| NCT00813501 | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a… | — | terminated | Dec 23, 2008 | City of Hope Medical Center | Terminated at the request of the study sponsor | Other (stated, no rule matched) |
| NCT00863096 | Human Papillomavirus Screening and Vaccine Readiness Program | — | withdrawn | Mar 17, 2009 | Public Health Research Institute, India | Unable to get the vaccine on time to offer it to the study population. | Other (stated, no rule matched) |
| NCT00629993 | Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved… | Phase 4 | terminated | Mar 6, 2008 | Columbia University | Principal Investigator left the institution | Investigator |
| NCT00496223 | A Phase I/II Study of Sunitinib and Dacarbazine | Phase 1 / Phase 2 | terminated | Jul 4, 2007 | H. Lee Moffitt Cancer Center and Research Institute | toxicities required dose reduction compromising effectiveness and PI left Moffitt | Safety / toxicity |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar… | Phase 2 | terminated | Jul 6, 2005 | Millennium Pharmaceuticals, Inc. | insufficient efficacy | Efficacy / futility |
| NCT00283634 | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small… | Phase 2 | terminated | Jan 30, 2006 | Millennium Pharmaceuticals, Inc. | insufficient efficacy | Efficacy / futility |
| NCT01140555 | A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery… | N/A | terminated | Jun 9, 2010 | Ethicon, Inc. | Further internal evaluation of the device was required. | Other (stated, no rule matched) |
| NCT00473616 | Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762… | Phase 1 | terminated | May 15, 2007 | AstraZeneca | Termination of the study was made after a full review of program data and assessment of the current… | Other (stated, no rule matched) |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin…(Glass-Art) | Phase 3 | terminated | Feb 14, 2008 | Bradmer Pharmaceuticals Inc. | Due to delay in site initiation and funding considerations | Funding |
| NCT00293332 | Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or… | Phase 2 | terminated | Feb 17, 2006 | University of California, San Francisco | Terminated due to low subject accrual | Enrollment / accrual |
| NCT00937664 | Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine | Phase 1 | terminated | Jul 13, 2009 | AstraZeneca | Termination of the study was made after a full review of program data and assessment of the current… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 26, 2011source: clinicaltrials